FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis

Analogues of the hepatokine fibroblast growth factor 21 (FGF21) are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unraveled, the mechanisms by which they alleviate liver...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Cong, Schönke, Milena, Spoorenberg, Borah, Lambooij, Joost M, van der Zande, Hendrik JP, Zhou, Enchen, Tushuizen, Maarten E, Andreasson, Anne-Christine, Park, Andrew, Oldham, Stephanie, Uhrbom, Martin, Ahlstedt, Ingela, Ikeda, Yasuhiro, Wallenius, Kristina, Peng, Xiao-Rong, Guigas, Bruno, Boon, Mariëtte R, Wang, Yanan, Rensen, Patrick CN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Immunology and Inflammation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928421/
https://www.ncbi.nlm.nih.gov/pubmed/36648330
http://dx.doi.org/10.7554/eLife.83075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928421/
https://www.ncbi.nlm.nih.gov/pubmed/36648330
http://dx.doi.org/10.7554/eLife.83075

Ejemplares similares